IPXL - Impax Laboratories, Inc.

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (3Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • A Performance Overview of Merck’s Cardiovascular Segment
    Market Realist

    A Performance Overview of Merck’s Cardiovascular Segment

    Merck & Co.’s (MRK) Zetia generated revenues of $165 million in the third quarter, reflecting a ~48% YoY (year-over-year) decline and a ~27% sequential decline. Zetia reported net revenues of $696 million in the first nine months of the year compared to $1 billion in the same period of 2017, reflecting a ~32% YoY decline.

  • We're sorry this is all we were able to find about this topic.